Funding news
Oblenio Bio logo

Oblenio Bio Secures $62.0

Recently funded · $62.0M Series bHospitals and Health CareUSView source

Get the full Oblenio Bio company profile

Access contacts, investors, buying signals & more

Open in Dashboard

The quest to transform treatment for severe autoimmune diseases just got a significant boost. Oblenio Bio, a biotech firm focused on putting the promise of immune reset within reach for millions of patients, has secured $62.0M in Series B funding.

The company is developing T-cell engagers as a novel therapeutic approach. This strategy aims to address underlying disease pathophysiology and achieve immune reset, potentially offering a new path for those suffering from debilitating autoimmune conditions.

Other United States companies recently funded

View all

Biggest recent Biotechnology rounds

Largest funding rounds in Biotechnology on Signalbase right now.

#CompanyAmount
1
Shockwave Medical logo

Shockwave Medical

United States

$13.1B
2
NeuroEM Therapeutics logo

NeuroEM Therapeutics

United States

$7.2B
3
GRAIL logo

GRAIL

United States

$7.1B
4
Illumina logo

Illumina

United States

$7.1B
5
RemeGen Biosciences logo

RemeGen Biosciences

United States

$5.6B

Other recent Series b rounds

Companies that recently closed a Series b round.

#CompanyAmount
1
ElevateAI logo

ElevateAI

$100.0M
2
Ollin Biosciences logo

Ollin Biosciences

United States

$330.0M
3
xCures Inc. logo

xCures Inc.

United States

$46.0M
4
PROPHESEE logo

PROPHESEE

France

$20.0M
5
Isometric logo

Isometric

United Kingdom

$400.0M
Oblenio Bio Secures $62.0 | Signalbase